Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.
OBJECTIVES: To analyse time to cardiovascular events and mortality in patients with type 2 diabetes (T2D) who received treatment intensification with insulin or a glucagon-like peptide-1 (GLP-1ar) analogue following dual therapy failure with metformin (MET) and sulphonylurea (SU). METHODS: A retrospective cohort study was conducted in 2003 patients who were newly treated with a GLP-1ar or insulin following dual therapy (MET+SU) failure between 2006 and 2014. Data were sourced from The Health Improvement Network database. Risks of major adverse cardiovascular events (MACE) (non-fatal myocardial infarction, non-fatal stroke and all-cause mortality) were compared between MET+SU+insulin (N=1584) versus MET+SU+GLP-1ar (N=419). Follow-up was for 5 years (6614 person-years). Propensity score matching analysis and Cox proportional hazard models were employed. RESULTS: Mean age was 52.8±14.1 years. Overall, the number of MACE was 231 vs 11 for patients who added insulin versus GLP-1ar, respectively (44.5 vs 7.7 per 1000-person-years adjusted HR (aHR): 0.27; 95% CI 0.14 to 0.53; p<0.0001). Insulin was associated with significant increase in weight compared with GLP-1ar (1.78 vs -3.93 kg; p<0.0001) but haemoglobin A1c reduction was similar between both treatment groups (-1.29 vs -0.98; p=0.156). In a subgroup analysis of obese patients (body mass index >30 kg/m(2)) there were 84 vs 11 composite outcomes (38.6 vs 8.1 per 1000 person-years; aHR: 0.31; 95% CI 0.16 to 0.61; p=0.001) in the insulin and GLP-1ar groups, respectively. CONCLUSIONS: In this cohort of obese people with T2DM, intensification of dual oral therapy by adding GLP-1ar analogue is associated with a lower MACE outcome in routine clinical practice, compared with adding insulin therapy as the third glucose-lowering agent.
Item Type | Article |
---|---|
Keywords | Adult, Aged, Biomarkers, blood, Blood Glucose, drug effects, metabolism, Cardiovascular Diseases, diagnosis, etiology, mortality, prevention & control, Cause of Death, Databases, Factual, Diabetes Mellitus, Type 2, complications, diagnosis, drug therapy, mortality, Drug Therapy, Combination, Female, Glucagon-Like Peptide 1, adverse effects, analogs & derivatives, therapeutic use, Hemoglobin A, Glycosylated, Humans, Hypoglycemic Agents, adverse effects, therapeutic use, Insulin, adverse effects, therapeutic use, Kaplan-Meier Estimate, Male, Metformin, therapeutic use, Middle Aged, Obesity, Propensity Score, Proportional Hazards Models, Retrospective Studies, Risk Assessment, Risk Factors, Sulfonylurea Compounds, therapeutic use, Time Factors, Treatment Outcome, United Kingdom |
ISI | 384437800014 |